Frisch, Avraham |  Ganzel, Chezi... -  《European Journal of Haematology》 - 2025,114(4) - 641～649 - 共9页

摘要：Molecular assessment of measurable residual disease (MRD) in NPM1-mutated AML patients is a powerful prognostic tool to identify the risk of relapse. There is limited data regarding MRD-guided decisio...

关键词： Acute myeloid leukemia |  Measurable residual disease |  NPM1 |  relapse

Ganzel, Chezi |  Frisch, Avraham... -  《British Journal of Haematology》 - 2025,206(2) - 551～555 - 共5页

摘要：This pilot study evaluated CPX-351 in adults with newly diagnosed, favourable-intermediate risk, FLT3-ITD-negative AML. Twenty patients received CPX-351 for induction, with six also receiving gemtuzum...

关键词： AML |  cardiotoxicity |  CPX-351 |  gemtuzumab ozogamicin |  MRD |  vyxeos |  CPX‐351

Frisch, Avraham |  Aumann, Shlomzion... -  《Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis》 - 2022,119 - 106902～106902 - 共7页

摘要：Remission assessment in acute myeloid leukemia has evolved over the recent years with the advent of molecular and flow-based minimal residual disease determination. Nonetheless, early time point such ...

关键词： D14 |  Acutemyeloidleukemia |  COLONY-STIMULATING FACTOR |  HIGH-DOSE CYTARABINE |  YOUNGER PATIENTS |  GEMTUZUMAB OZOGAMICIN |  COMPLETE REMISSION |  BLAST CLEARANCE |  OLDER PATIENTS |  G-CSF...

Shimony, Shai |  Canaani, Jonathan... -  《Annals of hematology》 - 2022,101(9) - 2001～2010 - 共10页

摘要：Patients with FLT3-mutated relapsed or refractory (R/R) acute myeloid leukemia (AML) have a dismal prognosis. Gilteritinib is a FLT3 tyrosine kinase inhibitor (TKI) recently approved for patients with...

关键词： Relapsed |  refractory AML |  FLT3 |  Gilteritinib |  MUTATIONS |  RECOMMENDATIONS |  CHEMOTHERAPY |  DIAGNOSIS |  PROGNOSIS

Wolach, Ofir |  Frisch, Avraham... -  《Annals of hematology》 - 2022,101(8) - 1719～1726 - 共8页

摘要：Venetoclax in combination with intensive therapies is explored in both the upfront and relapse/refractory (R/R) setting, and available data suggest that such regimens are effective albeit with added h...

关键词： High-risk AML |  Intensive chemotherapy |  Salvage |  Venetoclax |  RECOMMENDATIONS |  DIAGNOSIS

Ofran, Yishai |  Leiba, Ronit... -  《European Journal of Haematology》 - 2021,106(1) - 64～71 - 共8页

摘要：Objectives Midostaurin, a multikinase and FLT3 inhibitor, is the first non-chemotherapy agent approved and widely adopted for the treatment of FLT3-ITD acute myeloid leukemia (AML). Yet, its role in i...

关键词： acute myeloid leukemia |  allogeneic stem cell transplantation |  fms-like tyrosine kinase 3-internal tandem duplication |  midostaurin

Frisch, Avraham |  Rowe, Jacob M.... -  《British Journal of Haematology》 - 2020,191(5) - 682～691 - 共10页

摘要：After decades when intensive chemotherapy remained the only effective anti-acute myeloid leukaemia (AML) treatment, a torrent of novel, less toxic agents are about to revolutionise AML therapy. Prolon...

关键词： acute myeloid leukaemia |  older adults |  molecular profile |  intensive chemotherapy |  novel agents

Berger, Tamar |  Rozovski, Uri... -  《Annals of hematology》 - 2019,98(12) - 2711～2717 - 共7页

摘要：The addition of midostaurin, a FLT3-inhibitor, to intensive chemotherapy (IC) was previously shown to improve outcome of younger patients with FLT3-mutated AML. The toxicity and efficacy of adding mid...

关键词： Acute myeloid leukemia |  Midostaurin |  FLT3 mutation

Bitterman, Roni |  Hardak, Emilia... -  《Clinical infectious diseases》 - 2019,69(10) - 1805～1808 - 共4页

摘要：Invasive pulmonary aspergillosis (IPA) has dire consequences in hemato-oncological patients. We report our experience with performing routine baseline chest computed tomography for early diagnosis of ...

关键词： invasive pulmonary aspergillosis |  invasive fungal infection |  baseline chest CT |  acute myeloid leukemia |  hematologic malignancy

Shimony, Shai |  Canaani, Jonathan... -  《Annals of hematology》 - 2022,101(9) - 2011～2011 - 共1页